After failing to conclude mergers with InSite Vision and Auxilium Pharmaceuticals, Vancouver-based QLT has now agreed to combine with cash-strapped Aegerion Pharmaceuticals in an all-stock deal that will see the combined company renamed Novelion Therapeutics. With the deal, QLT will gain a global commercial infrastructure that it will hope to leverage for its Phase III-ready orphan drug zuretinol, which is being developed for inherited retinal diseases caused by underlying mutations in the RPE65 or LRAT genes.